Background-Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results-The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm 2 on optical coherence tomography and 0.17±0.26 mm 2 on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm 2 on intravascular ultrasound, P=0.003 and 0.77±1.33 m 2 on optical coherence tomography, P=0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Key Words: coronary artery disease ◼ coronary intervention and bioresorbable scaffold
T he first 2 publications on the first generation of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) have reported few seminal observations made at 6-month and 2-year follow-up using multiple imaging modalities: (1) complete bioresorption has been documented by optical coherence tomography (OCT), intravascular ultrasound (IVUS) grayscale, and IVUS radiofrequency backscattering; (2) physiologically or pharmacologically induced vasomotion has been restored in the scaffolded area; and (3) between 6 and 24 months, late luminal enlargement with plaque media regression without apparent remodeling has been established. [1] [2] [3] [4] However, at 6 months this first generation of polymeric scaffolds showed signs of shrinkage or late recoil resulting in an angiographic late luminal loss of 0.44 mm, which is in between the luminal loss observed with the bare-metal stent and the Xience V everolimus-eluting metallic stent at the same point of time.
The second generation of Absorb everolimus-eluting BVS, with changes in the design platform and manufacturing process, fully remediated this mechanical deficiency so that the scaffold area (SA) was found to be unchanged at 6 months by OCT. 5, 6 At 12-month follow-up, analysis by OCT and ultrasound confirmed the persistence of an unchanged SA without substantial loss in lumen area (LA), whereas vasomotion became again detectable. In other words, the mechanical integrity of the scaffold had partially subsided. Previous literature has already demonstrated that the restenotic process involving constrictive remodeling ceases to be active 4 months after balloon angioplasty. [7] [8] [9] These observations also substantiate the concept of restenosis with constrictive remodeling as a time-limited process, thereby validating the principle of a transient need for luminal scaffolding.
Metallic stents could possibly generate a large acute gain compared with polymeric scaffolds, but no randomized data are currently available. On the other hand, a previous historical angiographic assessment with the Xience V metallic everolimus-eluting stent at 2 years indicated an angiographic late loss of 0.33 mm, and it is current knowledge that the lumens of vessels treated with metallic stents do not exhibit any vasomotion. 10, 11 Bioresorbable scaffolds may be unable to generate an acute lumen gain comparable with metallic stents, but their use may possibly result, at long-term follow-up (24-36 months) , in a reduced luminal late loss or even potentially in a late lumen gain, with the additional benefit of the recovery of the vasomotor tone that could respond favorably to shear stress and pharmacological treatment. Accordingly, in the present investigation at 2 years, the protocol with optional vasomotion test with ergonovine and acetylcholine was replaced by a mandatory assessment of the vasodilatory capacity of the scaffolded segment by nitrates alone, and the luminal dimension after nitrate has become a major component of the angiographic primary end point in the ongoing randomized pivotal trial comparing Absorb with Xience Prime (ABSORB II). The second-generation Absorb BVS was tested in 101 patients of the ABSORB cohort B study. This cohort was subdivided into 2 subgroups of patients: the first group (B1) reported in the current study underwent invasive imaging with quantitative coronary angiography (QCA), IVUS, IVUSvirtual histology, and OCT at 6 and 24 months, whereas the second group (B2) underwent invasive imaging at 12 months, which will be repeated at 36 months. The purpose of the present report is to describe the first serial observation at 6 and 24 months of this second-generation Absorb BVS in the B1 group and to report the clinical follow-up at 24 months of the entire cohort (NCT00856856).
Methods

Study Population
The ABSORB cohort B trial is a multicenter single-arm trial assessing the safety and performance of the Absorb BVS (second generation, Abbott Vascular, Santa Clara) in the treatment of 101 patients with a maximum of 2 de novo native coronary artery lesions. The details of inclusion and exclusion criteria have been described previously.
5,12
Study Device
The Absorb BVS consists of a polymer backbone of Poly-L lactide coated with a thin layer of a 1:1 mixture of Poly-D, L-lactide polymer, and the antiproliferative drug everolimus to form an amorphous drug-eluting coating matrix containing 100 μg of everolimus/cm 2 of scaffold. The details of the device have been previously described. 5, 13 To enhance the mechanical strength of the struts and to reduce acute and late recoil, the strut design and the manufacturing process of the polymer were modified from the previous version of the device. First, the new design has in-phase zigzag hoops linked by bridges that allow a more uniform strut distribution, reduce maximum circular unsupported surface area, and provide more uniform vessel wall support and drug transfer. Second, a modified manufacturing process has resulted in a slower hydrolysis (in vivo degradation) rate of the polymer, thus preserving its mechanical integrity for a longer period of time.
Study Procedure
Target lesions were scaffolded after mandatory predilation. Postdilation with a balloon shorter than the implanted scaffold was allowed at the operator's discretion (if an optimal angiographic result was not obtained immediately after scaffold deployment). Additional stenting with Xience V for edge dissection or insufficient coverage of the lesion occurred in 3 patients. Treatment with aspirin was started at least 6 hours before the index procedure.
14 A loading dose of 300 mg of clopidogrel was administered before the procedure, followed by 75 mg daily for a minimum of 6 months.
WHAT IS KNOWN
• The first generation of fully bioresorbable everolimuseluting scaffold exhibited late recoil at 6 months, with a late lumen loss intermediate between bare-metal stent and drug-eluting stent.
• The second generation of everolimus-eluting bioresorbable vascular scaffold, with changes in the design platform and manufacturing process, fully remediated this mechanical deficiency, and the scaffold area was found to be unchanged at 6 months by optical coherence tomography (OCT).
• At 12 month follow-up, analysis by OCT and ultrasound confirmed the persistence of an unchanged scaffold area without substantial loss in lumen area, whereas vasomotion became again detectable.
WHAT THE STUDY ADDS
• From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm 2 on OCT and 0.17±0.26 mm 2 on intravascular ultrasound.
• Struts still recognizable on OCT at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm 2 on intravascular ultrasound, P=0.003 and 0.77±1.33 m 2 on OCT, P=0.016). The increase in scaffold area may be a prelude to the late lumen enlargement seen with the first generation.
• Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. October 2012
Definitions
The composite ischemia-driven major adverse cardiac event (MACE) was cardiac death, any myocardial infarction, and ischemia-driven target lesion revascularization (TLR) for a QCA diameter stenosis (DS) of ≥50%, with either symptoms or ischemia, or DS ≥70% at the time of scheduled or unscheduled angiography. For non-Q myocardial infarction, elevation of CK levels ≥2× the upper limit of normal with elevated CK-MB was required. 15 All events were adjudicated by an independent clinical event committee, and all imaging procedures (QCA, IVUS grayscale, IVUS-virtual histology, echogenicity, and OCT) were analyzed by an independent core laboratory (Cardialysis B.V., Rotterdam, the Netherlands).
Angiographic Assessment
In each patient, the treated segment and the periscaffold segments (defined by a length of 5 mm, proximal and distal to the scaffold edge) were analyzed by QCA postprocedure and at follow-up 1 using an interpolated method for the reference vessel diameter. 
Vasomotion Test
Changes in vasomotion (mean lumen diameter) before and after nitrate were assessed in paired matched angiographic view(s) in the scaffolded segment and in the 5-mm proximal and 5-mm distal adjacent segments. 2, 12, 16 
IVUS Grayscale Analysis
Treated vessels postprocedure and at follow-up were examined with phased array IVUS catheters (EagleEye; Volcano Corporation, Rancho Cordova, CA) using a pullback speed of 0.5 mm/second. The region of interest beginning 5 mm distal to and extending 5 mm proximal to the treated segment was examined. The vessel area, mean and minimal SA, mean and minimal LA, as well as intrascaffold neointimal area were measured using a computer-based contour detection program. 17 Incomplete apposition was defined as ≥1 scaffold struts separated from the vessel wall, whereas acquired late incomplete apposition was defined as incomplete apposition at follow-up that was not present postprocedure. For echogenicity assessment of polymeric struts at baseline and follow-up, we used a computer-aided grayscale value analysis program for strut characterization. 18, 19 
IVUS Radiofrequency Analysis
Backscattering of radiofrequency signals provides information on vessel wall tissue composition (IVUS-virtual histology). [20] [21] [22] [23] Four tissue components (necrotic core, red; dense calcium [DC], white; fibrous [F], green; and fibrofatty, light green) were identified with autoregressive classification systems and expressed as percentages (per cross-section, necrotic core+DC+fibrofatty+F=100%). 20, 21 The change in quantitative analyses of these areas between implantation and follow-up was used as a surrogate assessment of the chemical and structural alteration of the polymeric struts.
1,2,22-24
Optical Coherence Tomography
As an optional investigation, intravascular OCT imaging using either time domain OCT (M3 system; LightLab Imaging Westford, MA) or frequency domain OCT (C7XR system; LightLab Imaging) was performed at baseline and at follow-up. 13, [25] [26] [27] [28] [29] No OCT acquisition was performed with occlusion technique. The OCT measurements were performed with proprietary software for offline analysis (LightLab Imaging). Adjusting for the pullback speed, the analysis of continuous cross-sections was performed at each 1-mm longitudinal interval within the treated segment.
The main quantitative measurements (strut core area, strut area, LA, SA, incomplete scaffold apposition area, and neointimal area) required different analysis rules than with the metallic stents. 5, 6, 12, 30 Qualitatively, the diagnosis of early (periprocedural) structural strut discontinuity could be made: (1) if 2 struts overhang each other in the same angular sector of the lumen perimeter, with or without malapposition, or (2) if there was isolated strut(s) located more or less at the center of the vessel without obvious connection with other surrounding struts in 2-dimensional OCT. 5, 12 At follow-up, similar criteria were used, unless the struts were covered and incorporated into the vessel wall in 2-dimensional OCT. Three-dimensional OCT analysis of apparently isolated struts may be helpful in imaging their 3-dimensional connection with the global structure of the scaffold. 5, 12 The thickness of the coverage was measured for every strut between the abluminal side of the strut core and the lumen. Because the strut thickness is ≈150 µm, the strut was considered to be covered whenever the thickness of the coverage was above this threshold value.
5,12
Statistical Analysis
For binary variables, percentages were calculated. For continuous variables, normality distribution was tested with the KolmogorovSmirnov test and variables are presented as mean and SDs or median and interquartile ranges accordingly. Paired comparisons between postprocedure and follow-ups were performed by a Wilcoxon signed-rank test. Because no formal hypothesis testing was planned for assessing the success of the study, no statistical adjustment was applied. P values presented in this article are exploratory analyses only and should, therefore, be interpreted cautiously. For imaging assessment, truly serial analysis is presented in tables, whereas all available paired analysis of each time point is presented in the onlineonly Data Supplement.
Results
Cohort With Serial Imaging at 6 and 24 Months
Forty-five patients were enrolled (Figure 1 ), and the investigational device was successfully implanted in all patients (Table 1) . 5 Additional metallic drug-eluting stents were implanted in 3 lesions, either to treat a stenotic lesion located <5 mm distal to the Absorb BVS (1 case) or to seal an edge dissection induced by scaffold implantation (1 case) or predilation (1 case). In the latter case, myocardial enzyme release 2× above the upper limit of normal (CK 521 U/L with CK-MB 48 U/L) was documented with a transient occlusion of the treated vessel because of incomplete coverage of the dissection by the Absorb scaffold, which was ultimately treated by a metallic drug-eluting stent.
At 42 days, 1 patient with recurrent atypical angina underwent a nonischemia-driven repeat revascularization. Angiography revealed a nonsignificant stenosis of 23% DS, with OCT documentation of strut discontinuity happening at the index procedure. 5, 31, 32 In 1 patient, the planned angiography at 6 months disclosed a significant proximal edge restenosis (QCA, 64%; FFR, 0.72) of presumably iatrogenic origin because of the deep engagement of a left Amplatz catheter up to the mid portion of the right coronary artery at the index procedure. 5 At 12 months, 1 patient presented with recurrent angina, and angiography demonstrated a proximal edge restenosis, presumably because of angiographic miss of the balloon predilation at the index procedure.
33,34
Entire Cohort With Clinical Follow-Up at 2 Years
In total, 101 patients were enrolled in this study ( Figure 1 ). The 1-year follow-up has been previously reported. 12 The baseline characteristics of the entire cohort are presented in Table 1 . Between 1 and 2 years, 1 patient developed a lesion distal to the scaffold at follow-up and was treated by a metallic stent covering the distal part of the scaffold (TLR), whereas the second patient underwent a TLR for late restenosis of the scaffold on day 567.
During the 2-year follow-up, there were no possible, probable, or definite scaffold thromboses. 35 In summary, there were 3 non-q-wave myocardial infarction and 6 ischemicdriven TLR, which resulted in a 2-year MACE rate of 9.0%. Dual-antiplatelet therapy was maintained in 97% (98/101), 81.2% (82/101), and 24.8% (25/101) at 6 months, 12 months, and 24 months, respectively.
Quantitative Coronary Angiography
Truly serial angiographic analysis with intracoronary administration of nitrate before QCA at baseline and 6 and 24 months was available in 34 cases (Table 2) . Intracoronary nitrate was not administered in 1 patient, and therefore the patient was not included in the serial analysis (LL, −0.09 mm; MLD, 2.80 mm; %DS, 17%). In the serial analysis (n=34), the minimal luminal diameter decreased from 2.28 mm at baseline to 2.11 and 2.01 mm at 6 and 24 months, respectively. The initial late luminal loss at 6 months of 0.16 mm increased to 0.27 mm at 2 years. As a consequence, the intrascaffold DS increased from 15±6% at baseline to 19±8% at 6 months and 21±8% at 2 years without intrascaffold binary restenosis. Proximal and distal edge late loss at 2 years did not differ significantly from 6 months, but the proximal MLD postprocedure decreased significantly from 2.39 to 2.31 mm at 2 years.
In 1 patient, the mean proximal and distal diameter at 2 years were 1.94 and 1.87 mm, respectively, whereas at 2-year follow-up the maximal lumen diameter in the scaffolded segment was 3.75 mm, a change in dimension which fulfills the criteria of aneurysm (50% increase compared with the adjacent reference vessel). 36 With imputation, 2-year QCA data were available for 39 patients, including the imputed QCA values of the 3 patients who underwent a TLR at 42 days, 6 months, and 12 months, respectively, as well as the value of 1 patient who underwent 2-year angiography without nitrate administration and 1 patient without 6-month angiography but with 2-year angiographic follow-up ( Figure 1 ). The late loss of these 39 patients was 0.26±0.20 mm, and the overall in-segment binary restenosis rate of 5.1% was specifically because of 2 significant de novo narrowings in the proximal edges. The overall QCA data are presented in the online-only Data Supplement.
Intravascular Ultrasound
Serial IVUS analysis was available at 6 months and 2 years in 33 patients, with imputation of 1 IVUS data point collected before TLR (at 42 days) ( Table 3 ). In the other 2 TLR cases, one had no IVUS at baseline, whereas the other did not have IVUS at the time of the TLR. The change in mean vessel area indicated 2 serial significant positive remodeling steps, from baseline to 6 months and from 6 months to 2 years. The mean SA increased significantly from 6 months to 2 years, with an overall significant increase of 0.54 mm 2 between baseline and 2 years. In contrast, the minimal SA decreased significantly at 6 months but was stabilized at 24 months with a value of 5.34 mm 2 . The neointimal hyperplasia of 0.25 mm 2 detected by IVUS at 2 years was minimal, but there was a significant increase from 6 months to 2 years. As a result, the intra-SA obstruction was 3.78% at 2 years. Of note, the mean LA significantly increased from 6 months to 2 years, whereas the minimum LA remained stable between 6 and 24 months. Both parameters initially decreased modestly but significantly from baseline to 6 months. The total plaque/media area including the strut area increased in 2 significant steps, at 6 months and at 2 years. Incomplete appositions by IVUS, seen initially in 3 patients at baseline, were finally observed in 2 patients.
The relative measurement of DC area, previously used in ABSORB cohort A as a surrogate parameter for bioresorption, decreased from baseline to 2 years (P=0.049; Table 4 ), whereas there were no significant changes in % necrotic core area. Percentage of hyperechogenicity area, a more sensitive parameter to measure degradation of polymeric material, 37 decreased from a baseline value of 25.3% to 20.4% at 6 months and to 13.8% at 2 years ( Figure 2 ). 
Optical Coherence Tomography
The serial analysis of the mean SA on OCT in 23 patients showed a progressive increase from 7.47 mm 2 at baseline to 7.70 and 8.24 mm 2 at 6 and 24 months, respectively (Table 5 ). This global increase at 2 years was significant, whereas the minimal SA remained unchanged between 6 months and 2 years. In the first 6 months, the strut core area was unchanged but at 24 months showed a clear decrease (−28.30±9.79%) representing optical signs of bioresorption. The mean lumen and mean flow area remained unchanged between 6 months and 2 years, whereas the minimal value of these parameters continued to decrease significantly between 6 months and 2 years.
The coverage of struts at 2 years was almost complete, with only 1% of struts remaining uncovered. Incomplete strut apposition, seen initially in 11 scaffolds, was still detected in only 1 scaffold at 2 years. Of the 560 analyzed frames, 13 frames (2.3%) contained any intraluminal defect, with a median area of 0.13 mm 2 (interquartile range, 0.09-0.25 mm 2 ).
Discontinuity of the struts as described in the Methods section was observed in 6 cases from baseline to 2 years (cases 1-6 in Table 6 ). 5 One case of periprocedural strut discontinuity caused by overstretching of a scaffold has been previously reported. 31 One baseline OCT was not available but strut discontinuity was detected at 6 months and persisted at 2 years. Two cases had no discontinuities at baseline but showed signs of discontinuity at 6 months: one persisted and the other resolved at 2 years. In the 2 remaining cases, discontinuity was detected at baseline, persisted at 6 months, but in one of the cases resolved at 2 years. None of these patients experienced MACEs, and all of them had discontinued their dual-antiplatelet therapy at 13 months. Furthermore, there were 2 additional cases identified with OCT only at 2 years (cases 7 and 8 in Table 6 ), and the core laboratory identified 7 cases in a frame-to-frame analysis (200 micron per frame) with overhanging struts that were fully covered and incorporated into the vessel wall.
Discussion
The main findings of the present study can be summarized as follows. On IVUS, significant increases in mean vessel area, total plaque area, and plaque area behind the struts, together with an increase in neointima growth between 6 and 24 months, Prior target vessel intervention, n (%)
Prior myocardial infarction, n (%)
25 (25) 16 (36) 9 (16) Target vessel
Left anterior descending, n (%)
44 (43) 17 (38) 27 (47) Left circumflex, n (%) 24 (24) 12 (27) 12 (21) Right coronary artery, n (%) 34 (34) 16 (36) 18 (32) AHA/ACC lesion classification (55) 20 (45) 35 (63) B2, n (%) 40 (40) 22 (50) 18 (32) C, n (%) 4 (4) 1 (2) suggest a persistent proliferative healing process between 6 and 24 months. Because the tissue growth is accommodated by an expansive remodeling, there is no late compromise of the lumen between 6 and 24 months. The persisting presence of the struts imaged by ultrasound and light allowed for the accurate measurement of scaffolded contours that definitely showed an increase in its area, confirming the disappearance of the mechanical integrity of these structures.
The serial analysis of OCT confirmed the significant enlargement of the mean SA with stabilization of the minimal SA. Although the struts are still discernible on OCT and ultrasound, there are clear quantitative ultrasonic and optical surrogate signs of bioresorption of the struts. The precise measurement of neointimal area on OCT confirmed the persistence of tissue growth detected on IVUS between 6 months and 2 years. Whereas minimal flow area and minimal LA-these measurements have become interchangeable at 2 years-showed an additional decrease between 6 months and 2 years, the mean LA and mean flow area remained stable. At 2 years, ≈99% of struts were covered, and only 1 scaffold showed malapposition.
Serial quantitative angiography showed a significant increase of the in-scaffold late loss from 0.16 mm at 6 months to 0.27 mm at 2 years (P=0.005). Between 6 months and 24 months, no significant loss in the proximal and distal edges was seen. Only 2 cases of binary restenoses (%DS >50%) were detected at the proximal edges. The hierarchical MACE rate was 6.8% (3 events), 1 non-Q wave and 2 ischemic-driven TLR.
Changes in Late Luminal Loss Over Time
Serial late luminal loss assessment showed a significant increase from 0.16 to 0.27 mm (Figure 3) . This is the result of late neointimal growth, as demonstrated by OCT analysis (increased by 0.68 mm). 2 In this respect, it is interesting to note that, in 
Still Increasing Neointima and Positive Remodeling
As assessed by ultrasound and OCT, the neointimal tissue grew significantly between 6 months and 2 years, indicating that the proliferative healing process is not yet fully abated, which confirms the observation made in preclinical models showing remnants of inflammatory response at 2 years with the presence of giant cells and granulomas. 38 Conversely, it has been clearly established that no granuloma/giant cells could be detected at 3 and 4 years in the area of presumed implantation of polymeric struts that are no longer discernible at that point of time.
At 3 and 4 years in our porcine model using the same polymer and formulation as in the current study, substantial thinning of vessel wall has been demonstrated that could be translated to the human situation as late lumen enlargement, as seen at 2 years in the cohort A study. 2 Noteworthy is that no expansive remodeling was seen at 2 years in the cohort A patients using the same polymer and formulation but with a faster bioresorption rate.
2
Vasomotion After Intracoronary Nitrate
At variance with the vessel caged by metallic structures, a vessel transiently scaffolded by bioresorbable materials is able to exhibit vasoconstriction and vasodilation. 2, 39 Therefore, at longterm follow-up a clear difference in vasomotricity could be demonstrated in favor of the bioresorbable scaffold. 2, 5 Multiple tests involving ergonovine, acetylcholine, and nitrate have been proposed; logistically, the administration of nitrate represents the most easily performed test. In the ongoing international pivotal trial, we have included as a powered primary end point the change in mean lumen diameter before and after intracoronary administration of nitrate (increase in mean luminal dimension of 0.07 mm with an SD of 0.20 mm). In the present trial, we tested this concept and demonstrated a small but statistically significant increase in mean lumen diameter after nitrate of 0.034±0.09 mm (P=0.035). The accuracy and precision of minimal lumen diameter and reference diameter of QCA in repeated measurement are 0.00 and 0.005 mm and 0.10 and 0.12 mm, respectively. 40, 41 However, of the 33 vessels only 19 showed vasodilation, 5 remained unchanged, and 9 demonstrated vasoconstriction. It was also documented that the mean blood pressure decreased on average by 13.6±6.4%, immediately after the intracoronary injection of nitrate before the coronary angiography. It is hypothesized that in some patients paradoxical vasoconstriction occurred as result of the baroreceptor reflex with increase in sympathetic tone and release of norepinephrine with a secondary stimulation of α-1 receptors of the coronary vasculature. 42, 43 In the ongoing international pivotal trial, investigators have been requested to wait for a full recovery of the mean blood pressure in an attempt to mitigate these neurovegetative reflexes. Normally distributed values are expressed as mean±SD, whereas non-normally distributed values are presented as mean±SD and median (interquartile ranges).
Discrepancy Between Change in IVUS Area and OCT Area Between 6 and 24 Months
Between 6 months and 2 years, we detected a slight but significant increase in mean LA with IVUS, with no change in minimal LA, whereas with OCT we demonstrated a decrease in the minimal LA with no changes in mean LA. LAs of native coronary arteries as measured by IVUS have been shown to be larger than the same areas measured by OCT, a difference that has to be attributed to differences in resolution and in the physics of backscattering of ultrasound and light from in vivo tissue. 44 When compared (n=19), the analysis of luminal areas over time is made more complex by the differences of the 2 techniques (Figure 4 ). This basic difference in detection of luminal contour is dynamically affected at follow-up as illustrated in Figure 4 and explains the significant decrease in minimal LA (between 6 months to 2 years) as assessed by OCT, versus the absence of changes seen in IVUS.
Signs of Resorption on IVUS and OCT
To date, echogenicity is the most sensitive method in vivo to detect biodegradation of the polymeric struts. The percentage of hyperechogenic tissue was 25.3%, 20.4%, and 13.8% at baseline, 6 months, and 2 years, respectively. These figures are consistent with those observed in the other cohort (B2) at baseline and 12 months, 23.5% and 18.3%, respectively, in Figure 2 . The use of ultrasound to monitor the degradation process of biopolymers has been proposed previously and was tested in an in vitro setup. Wu et al 45 showed that the degradation behavior of biodegradable polymers can be closely monitored by ultrasound techniques.
Pseudo DC on virtual histology seems to be a less sensitive surrogate for bioresorption. The percentage of DC was 31.2%, 29.8%, and 27.6% at baseline, 6 months, and 2 years, respectively. These figures are somewhat less aligned with the percentages observed in the other cohort (B2) at baseline and 12 months, 30.2% and 24.4%, respectively, although both long-term changes reached statistically significant levels. 12 The interpretation of OCT changes is greatly facilitated by the long-term comparison of OCT images and the histology in the porcine model at 2, 3, and 4 years. 38 At 2-year follow-up, the translucent core of the struts in our patients was still highly visible, similar to that observed in the porcine model; however, the area of the strut core was found to be significantly decreased, with some struts exhibiting blurred contours and some intracore scattering. Gel permeation chromatography analysis of tissue explants has demonstrated the virtual absence of polylactide, and conventional staining of histological sections with Alcian Blue has demonstrated the presence of proteoglycans that do not backscatter the light. In the course of the third year, it is expected that, similar to the porcine model, the struts will become indiscernible by OCT, which corresponds in histology to the filling process of the strut void by connective tissue ( Figure 5 ). QCA indicates quantitative coronary angiography; DS, diameter stenosis; OCT, optical coherence tomography; TLR, target lesion revascularization; BL, baseline; 6M, 6 months; 2Y, 2 years; +, strut discontinuity is observed on OCT; −, strut discontinuity is not observed on OCT; na, OCT is not available.
Quantitative analysis was performed in angiography at 1 mo before TLR. *The patient received metallic stent in the bioresorbable vascular scaffold at 1 mo. 
SA Increase Suggests a Yielding Process of the Scaffold
On IVUS and OCT, there are clear signs of late enlargement of the SA, which intuitively suggests the loss of mechanical integrity of the scaffold with possible discontinuity of struts. At 1 year, vasomotion test in cohort B2 had already demonstrated the transient dynamic plasticity of the scaffold.
12 At 2 years, discontinuity of the scaffold allows further dynamic changes in vessel architecture, such as late lumen enlargement.
Strut Discontinuity at 2 Years, a Common Sign of Bioresorption
Strut discontinuity, only detectable on OCT, can be primarily the result of acute overstretching of the polymeric device at the time of implantation and postdilation. 5, 31, 32 The morphological description of the OCT signs of discontinuity immediately postprocedure has been previously reported, and 3 cases were observed in the present series. One of them was diagnosed by the operator and treated by implantation of a metallic stent at 42 days 5, 31 ; 2 other cases were retrospectively diagnosed by the core laboratory. At follow-up, persistent or acquired signs of discontinuity on OCT are reported in Table 6 . Altogether, struts discontinuities with or without vessel wall incorporation were detected by the core laboratory in one third of the cases.
Loss of mechanical integrity of the scaffold structures with discontinuity of struts is a programmed and expected event, considering the biodegradable nature of the device. These microscopic changes can only be detected by OCT with its high imaging resolution (10-20 micron) . Angiography and its quantitative analysis did not reveal any of these subtle changes, and angiographic DS of these patients were systematically <50% (Table 6 ). To date, no MACEs have been associated with the documentation of strut discontinuity on OCT. Of note, all these patients discontinued their dual-antiplatelet therapy at 13 months. In the ABSORB cohort A study, using a faster biodegradable material, intraluminal struts connected by tissue bridges were documented at 6 months that disappeared by full bioresorption and incorporation into the vessel wall at 2 years ( Figure 6 ); a similar phenomenon might be expected at 3 to 4 years with the current version of the more slowly bioresorbing scaffold.
Comparison of the First and Second Generation at 2 Years
With the first generation, OCT and IVUS showed at 6 months a substantial alteration of strut and at 24 months complete disappearance of polymeric struts on OCT in 34%. With the second generation, the presence of the polymeric struts on OCT remained basically unchanged between 6 and 24 months. However, the strut core area decreased homogeneously by ≈25%, and both generations exhibited pharmacologically induced vasomotion at 24 months.
The second generation of bioresorbable scaffold has a more controlled and longer duration of resorption than the first generation of device. This prevents the so-called late recoil observed, with the first generation accounting for a late loss of 0.44 mm at 6 months and 0.46 mm at 2 years. The longer resorption of the second generation resulted, as a matter of fact, in a smaller lumen loss of 0.19 mm at 6 months and 0.27 mm at 2 years. Nevertheless, we have demonstrated in cohort B2 that vasomotion was already restored at 1 year, implying that the mechanical integrity of the scaffold has already subsided. However, the prolonged duration of resorption might be responsible for the significant (potentially transient) increase in plaque media behind the struts and expansive remodeling seen at 2 years. Further follow-up at 3 years will unravel the and optical coherence tomography (OCT) investigation, comparable OCT and IVUS cross-section (side branch) images are shown. The IVUS (20 MHz) primarily detected the highly reflective endoluminal surface of polymeric struts and is basically unable to detect with precision the endoluminal contour of the vessel wall between polymeric struts apposed but not embedded in the vessel wall. In other words, the delineation of luminal contour on IVUS after scaffold implantation relies mainly on the bright interface created by the presence of polymeric struts. In contrast, luminal dimension as measured by OCT truly reflect and delineate the endoluminal interface of the vessel wall behind the polymeric struts 5, 12 : the polymeric struts do not create abluminal shadowing and perfectly allow the detection of luminal contours behind the struts. At follow-up, neointimal tissue grows between polymeric struts and covers the top of the polymeric struts; this neointimal tissue (in between and on top of struts) is exquisitely detectable by OCT, showing the struts encapsulated by the neointima, whereas the lumen boundaries detected by IVUS remained mainly determined by the blooming brightness of not yet fully resorbed polymeric struts. This basic difference in detection of luminal contour is dynamically affected at follow-up by tissue growth as illustrated in figure and potentially explains the significant decrease in minimal lumen area (between 6 months and 2 years) as assessed by OCT, vs the absence of changes seen in IVUS (see table included in the figure).
ultimate biological response of the vessel wall to the new generation of scaffold.
In the first generation, no remodeling was observed between 6 and 24 months, whereas wall thinning and late lumen enlargement were documented by IVUS and OCT. With the second generation, we observed by IVUS a significant expansive remodeling with plaque media growth, SA enlargement, and late lumen enlargement, whereas the late lumen enlargement was not significant on OCT presumably because of differences in the methodology of imaging analysis as illustrated and explained in Figure 4 . Based on the preclinical investigation with imaging observation up to 4 years, we expected in our patients that a late wall thinning would occur and be accompanied by a late lumen enlargement, possibly with normalization of the vessel wall area. In summary, the benefit of second generation is the avoidance of the late recoil (SA reduction) at 6 months with an angiographic late loss comparable with the metallic everolimus-eluting stents. The 24-month follow-up with imaging suggests persistence of proliferating healing process but disclosed a new interesting phenomenon, namely the enlargement of the SA that could herald further late lumen enlargement at 3 and 4 years.
Conclusion
In conclusion, at 2 years, the scaffold is still detectable by various imaging modalities. However, its mechanical integrity must have subsided, as indicated by the dynamic vasomotion, and the structural increase in the SA is demonstrated by IVUS and OCT. Tissue growth on OCT and IVUS increased between 6 months and 2 years, suggesting an ongoing biological proliferative healing process. Discrepancy between the late enlargement between 6 months and 2 years on IVUS and the lumen reduction on OCT are methodologically explainable. Based on the animal model, late lumen enlargement (demonstrable on OCT) and wall thinning (demonstrable on IVUS) are expected to be seen at the 3-year follow-up of cohort B2 and in the ongoing randomized international trial comparing the Absorb BVS with the Xience Prime metallic everolimus-eluting stent.
Sources of Funding
This study was sponsored by Abbott Vascular (Santa Clara, CA). In one of the cases of strut discontinuity, 1 strut at 6 months is isolated in the close vicinity of the OCT catheter (D); on the next 2 consecutive cross-sections, first 2 struts overhang each other partially (white arrows in E) and then merge with the vessel wall (F). At 24 months, not a single cross-section on OCT (5 frames/mm) was found with an isolated strut (G-I); a bridge connecting the strut with the vessel wall is seen on each consecutive cross-section (G). Molecular weight starts to decrease as soon as the polymer gets in contact with aqueous milieu. Between 6 and 12 months, the scaffold loses its radial strength because of the partial degradation of the polylactide. At 24 months, the mass of the polymer has disappeared completely.
9 Middle panel, Optical coherence tomography appearance in humans (at 0, 6, 12, and 24 months) and in porcine coronary model at 36 and 48 months. The strut voids are covered and encapsulated by neointimal tissue, at 24 months in humans as in animals. Lower panel, Histological microphotograph after implantation of Absorb in a porcine coronary artery model (elastin staining at baseline, hematoxylin-eosin staining at 6 and 12 months, trichrome staining at 24 and 36 months, and Movat at 48 months). 38 At 24 months, the polylactide has fully disappeared and been replaced by Alcian Blue (not shown in the illustration). At 36 months, the proteoglycan will be replaced by connective tissue so that the strut footprint will be indiscernible at 4 years in histology and optical coherence tomography.
